|
Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613 EISSN: 0253-7613
Vol. 37, No. 5, 2005, pp. 320-324
|
Bioline Code: ph05082
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Indian Journal of Pharmacology, Vol. 37, No. 5, 2005, pp. 320-324
en |
"Quick Cycle" neoadjuvant chemotherapy in squamous cell carcinoma of cervix
Taneja A, Rajaram Shalini, Agarwal S, Singh KC, Sahni S, Goel N
Abstract
Objective: To evaluate the efficacy and safety of a 'Quick cycle' neoadjuvant chemotherapeutic regime in squamous cell carcinoma (SCC) of cervix and monitor the response to chemotherapy using Squamous Cell Carcinoma Antigen (SCC-Ag) as tumor marker.
Materials and Methods: Thirty patients with SCC of cervix (Stage I-IV) entered the study to receive three courses of multiagent neoadjuvant chemotherapy (vincristine, cisplatin and bleomycin) in a weekly regime. SCC-Ag was evaluated in these patients' pre and post-chemotherapy.
Results: Patients with stage IB2 had a complete response and two of seven patients with stage IIB became operable. The overall response rate was 47.8% and complete response rate was 8.7%. Decrease in tumor volume post-chemotherapy was significant (P<0.002). Toxicity including myelosuppression was minimal. A statistically significant decrease in SCC-Ag (stage II and III) was seen post-chemotherapy (P <0.04 and 0.005, respectively).
Conclusion: The weekly chemotherapeutic regime was found to be safe and effective and SCC-Ag is a useful tumor marker for monitoring response to chemotherapy.
Keywords
Cancer cervix, SCC-Antigen, tumor marker
|
|
© Copyright 2005 Indian Journal of Pharmacology. Alternative site location: http://www.ijp-online.com
|
|